Non-Small-Cell Lung Cancer (NSCLC) continues to pose a significant health and economic challenge as populations age globally, affecting millions of patients and causing over 19% of total deaths globally each year. Oncogenic mutations have attracted more attention as carriers are eligible for targeted treatments and disease outcome can be modified based on the presence of specific mutations.

Authors: Olulade Ayodele, MBBS, MPH; Nicole Zhang, MPH

DRG becomes Clarivate

View Now